Neuren Pharmaceuticals Limited (ASX:NEU)
Australia
· Delayed Price · Currency is AUD 12.35
+0.03 (0.24%)
At close: Mar 6, 2026
Neuren Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 64.63 | 136.73 | 231.93 | 14.55 | - | Upgrade
|
| Other Revenue | 0.02 | 80.11 | 0.02 | 0.86 | 3.2 | Upgrade
|
| Revenue | 64.65 | 216.83 | 231.94 | 15.42 | 3.2 | Upgrade
|
| Revenue Growth (YoY) | -70.19% | -6.51% | 1404.46% | 382.23% | 345.89% | Upgrade
|
| Cost of Revenue | 36.39 | 32.97 | 26.75 | 12.71 | 9.52 | Upgrade
|
| Gross Profit | 28.26 | 183.86 | 205.19 | 2.71 | -6.32 | Upgrade
|
| Selling, General & Admin | 6.22 | 4.7 | 5.95 | 3.44 | 1.91 | Upgrade
|
| Operating Expenses | 6.22 | 4.7 | 5.95 | 3.44 | 1.91 | Upgrade
|
| Operating Income | 22.04 | 179.16 | 199.25 | -0.73 | -8.23 | Upgrade
|
| Interest & Investment Income | 12.16 | 11.01 | 5.69 | 0.39 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | 8.03 | -7.24 | 2.43 | 1.23 | 0.4 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.3 | - | -2.23 | -0.7 | - | Upgrade
|
| EBT Excluding Unusual Items | 38.93 | 182.94 | 205.14 | 0.18 | -7.79 | Upgrade
|
| Pretax Income | 38.93 | 182.94 | 205.14 | 0.18 | -7.79 | Upgrade
|
| Income Tax Expense | 8.49 | 40.9 | 48.06 | - | - | Upgrade
|
| Net Income | 30.44 | 142.04 | 157.08 | 0.18 | -7.79 | Upgrade
|
| Net Income to Common | 30.44 | 142.04 | 157.08 | 0.18 | -7.79 | Upgrade
|
| Net Income Growth | -78.57% | -9.57% | 85270.11% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 128 | 128 | 127 | 126 | 118 | Upgrade
|
| Shares Outstanding (Diluted) | 131 | 131 | 131 | 129 | 119 | Upgrade
|
| Shares Change (YoY) | -0.01% | 0.01% | 1.44% | 8.76% | 10.71% | Upgrade
|
| EPS (Basic) | 0.24 | 1.11 | 1.24 | 0.00 | -0.07 | Upgrade
|
| EPS (Diluted) | 0.23 | 1.09 | 1.20 | 0.00 | -0.07 | Upgrade
|
| EPS Growth | -78.57% | -9.58% | 120020.00% | - | - | Upgrade
|
| Free Cash Flow | 125.39 | -11.28 | 184.89 | 3.58 | -9.98 | Upgrade
|
| Free Cash Flow Per Share | 0.96 | -0.09 | 1.41 | 0.03 | -0.08 | Upgrade
|
| Gross Margin | 43.71% | 84.80% | 88.47% | 17.55% | -197.65% | Upgrade
|
| Operating Margin | 34.09% | 82.63% | 85.90% | -4.75% | -257.52% | Upgrade
|
| Profit Margin | 47.08% | 65.51% | 67.72% | 1.19% | -243.79% | Upgrade
|
| Free Cash Flow Margin | 193.95% | -5.20% | 79.71% | 23.22% | -312.17% | Upgrade
|
| EBITDA | 22.06 | 179.18 | 199.26 | -0.72 | -8.23 | Upgrade
|
| EBITDA Margin | 34.13% | 82.64% | 85.91% | -4.68% | -257.27% | Upgrade
|
| D&A For EBITDA | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | Upgrade
|
| EBIT | 22.04 | 179.16 | 199.25 | -0.73 | -8.23 | Upgrade
|
| EBIT Margin | 34.09% | 82.63% | 85.90% | -4.75% | -257.52% | Upgrade
|
| Effective Tax Rate | 21.82% | 22.36% | 23.43% | - | - | Upgrade
|
| Revenue as Reported | 84.84 | 227.85 | 240.06 | 17.03 | 3.64 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.